Literature DB >> 6546809

Potentiation of opiate analgesia and apparent reversal of morphine tolerance by proglumide.

L R Watkins, I B Kinscheck, D J Mayer.   

Abstract

Exogenous cholecystokinin selectively antagonizes opiate analgesia, which suggests that endogenous cholecystokinin may act physiologically as an opiate antagonist and may play a role in opiate tolerance. The use of the selective cholecystokinin antagonist proglumide provided a test of these hypotheses in rats that were either inexperienced with or tolerant to opiates. Proglumide potentiated analgesia produced by morphine and endogenous opiates and seemed to reverse tolerance. These results suggest that endogenous cholecystokinin systems oppose the action of opiates.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6546809     DOI： 10.1126/science.6546809

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


  30 in total

Review 1.  Cellular mechanisms of neuropathic pain, morphine tolerance, and their interactions.

Authors:  D J Mayer; J Mao; J Holt; D D Price
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-06       Impact factor: 11.205

2.  Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists.

Authors:  Yeon Sun Lee; Richard S Agnes; Hamid Badghisi; Peg Davis; Shou-wu Ma; Josephine Lai; Frank Porreca; Victor J Hruby
Journal:  J Med Chem       Date:  2006-03-09       Impact factor: 7.446

3.  Partial retro-inverso, retro, and inverso modifications of hydrazide linked bifunctional peptides for opioid and cholecystokinin (CCK) receptors.

Authors:  Yeon Sun Lee; Richard S Agnes; Peg Davis; Shou-wu Ma; Hamid Badghisi; Josephine Lai; Frank Porreca; Victor J Hruby
Journal:  J Med Chem       Date:  2007-01-11       Impact factor: 7.446

Review 4.  Mu opioids and their receptors: evolution of a concept.

Authors:  Gavril W Pasternak; Ying-Xian Pan
Journal:  Pharmacol Rev       Date:  2013-09-27       Impact factor: 25.468

Review 5.  The "toll" of opioid-induced glial activation: improving the clinical efficacy of opioids by targeting glia.

Authors:  Linda R Watkins; Mark R Hutchinson; Kenner C Rice; Steven F Maier
Journal:  Trends Pharmacol Sci       Date:  2009-09-15       Impact factor: 14.819

6.  Proceedings of the British Pharmacological Society. Ireland, 6th-8th July, 1988. Abstracts.

Authors: 
Journal:  Br J Pharmacol       Date:  1988-10       Impact factor: 8.739

Review 7.  Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance.

Authors:  John T Williams; Susan L Ingram; Graeme Henderson; Charles Chavkin; Mark von Zastrow; Stefan Schulz; Thomas Koch; Christopher J Evans; Macdonald J Christie
Journal:  Pharmacol Rev       Date:  2013-01-15       Impact factor: 25.468

8.  Blockade of tolerance to morphine but not to kappa opioids by a nitric oxide synthase inhibitor.

Authors:  Y A Kolesnikov; C G Pick; G Ciszewska; G W Pasternak
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-01       Impact factor: 11.205

9.  Involvement of cholecystokinin receptors in the control of striatal dopamine autoreceptors.

Authors:  S Tanganelli; K Fuxe; G von Euler; L F Agnati; L Ferraro; U Ungerstedt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-09       Impact factor: 3.000

10.  Role of protein kinase C and mu-opioid receptor (MOPr) desensitization in tolerance to morphine in rat locus coeruleus neurons.

Authors:  C P Bailey; J Llorente; B H Gabra; F L Smith; W L Dewey; E Kelly; G Henderson
Journal:  Eur J Neurosci       Date:  2009-01       Impact factor: 3.386
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.